{"id":"gsk1562902a","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in inflammatory cells, which suppresses the release of pro-inflammatory cytokines and chemokines. This mechanism reduces airway inflammation and mucus production, making it potentially beneficial for chronic inflammatory airway diseases. The drug was developed to provide anti-inflammatory effects with improved tolerability compared to earlier PDE4 inhibitors.","oneSentence":"GSK1562902A is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:38.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT00449670","phase":"PHASE3","title":"Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-24","conditions":"Influenza, Influenza Vaccines","enrollment":1206},{"nctId":"NCT00430521","phase":"PHASE2","title":"Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-05","conditions":"Influenza, Influenza Vaccines","enrollment":512},{"nctId":"NCT00397215","phase":"PHASE2","title":"Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-17","conditions":"Influenza","enrollment":437},{"nctId":"NCT01323946","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-18","conditions":"Influenza","enrollment":113},{"nctId":"NCT00502593","phase":"PHASE2","title":"Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-23","conditions":"Influenza","enrollment":138},{"nctId":"NCT01379937","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-28","conditions":"Influenza","enrollment":520},{"nctId":"NCT00812981","phase":"PHASE3","title":"A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-15","conditions":"Influenza","enrollment":320},{"nctId":"NCT00652743","phase":"PHASE3","title":"Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-23","conditions":"Influenza","enrollment":845},{"nctId":"NCT00319098","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Influenza","enrollment":5075},{"nctId":"NCT00506350","phase":"PHASE2","title":"Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-01","conditions":"Influenza","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK1562902A","genericName":"GSK1562902A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK1562902A is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells. Used for Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}